DelveInsight’s, “Autosomal dominant polycystic kidney disease Pipeline Insight 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Autosomal dominant polycystic kidney disease pipeline landscape. It covers the Autosomal dominant polycystic kidney disease pipeline drug profiles, including Autosomal dominant polycystic kidney disease clinical trials and nonclinical stage products. It also covers the Autosomal dominant polycystic kidney disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Autosomal Dominant Polycystic Kidney Disease Pipeline Report

 

• DelveInsight’s Autosomal Dominant Polycystic Kidney Disease Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Autosomal Dominant Polycystic Kidney Disease treatment.

 

• The leading Autosomal Dominant Polycystic Kidney Disease Companies includes Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others.

 

• Promising Autosomal Dominant Polycystic Kidney Disease Pipeline Therapies includes GLPG2737, Bardoxolone methyl, Tesevatinib/KD019, RGLS8429, AT-20494, XRx-008, and others.

 

• The Autosomal Dominant Polycystic Kidney Disease companies and academics that are working to assess challenges and seek opportunities that could influence Autosomal dominant polycystic kidney disease R&D. The Autosomal Dominant Polycystic Kidney Disease pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Autosomal Dominant Polycystic Kidney Disease Pipeline treatment landscape of the report, click here @ Autosomal Dominant Polycystic Kidney Disease Pipeline Outlook

 

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the formation of cysts within the kidneys. Symptoms caused by cyst formation in the kidneys include high blood pressure (hypertension), pain on the sides of the body between the last rib and the hip (flank pain), blood in the urine (hematuria) and progressively poor function of the kidneys (kidney insufficiency). 

 

Recent Developmental Activities in the Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

 

• In December 2020, we announced the first dosing with GLPG2737 in the Phase 2 MANGROVE trial in patients with ADPKD and in November 2021 full patient recruitment with topline results anticipated in the first half of 2023.

 

• Bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of CKD caused by ADPKD, EAGLE, an open-label, extended access trial in patients with CKD caused by Alport syndrome who participated in the CARDINAL trial and patients with ADPKD who participated in the FALCON trial, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by Kyowa Kirin in Japan.

 

For further information, refer to the detailed Autosomal Dominant Polycystic Kidney Disease Unmet Needs, Autosomal Dominant Polycystic Kidney Disease Market Drivers, and Autosomal Dominant Polycystic Kidney Disease Market Barriers, click here for Autosomal Dominant Polycystic Kidney Disease Ongoing Clinical Trial Analysis

 

Autosomal Dominant Polycystic Kidney Disease Emerging Drugs Profile

 

• GLPG2737: Galapagos NV

GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD).

 

• Bardoxolone methyl: Reata Pharmaceuticals

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA and European Commission have granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”).

 

Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Autosomal dominant polycystic kidney disease. The companies which have their Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

 

Request a sample and discover the recent advances in Autosomal Dominant Polycystic Kidney Disease Ongoing Clinical Trial Analysis and Medications, click here @ Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

 

Scope of the Autosomal Dominant Polycystic Kidney Disease Pipeline Report

 

• Coverage- Global

 

• Autosomal Dominant Polycystic Kidney Disease Companies- Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others.

 

• Autosomal Dominant Polycystic Kidney Disease Pipeline Therapies- GLPG2737, Bardoxolone methyl, Tesevatinib/KD019, RGLS8429, AT-20494, XRx-008, and others. 

 

• Autosomal Dominant Polycystic Kidney Disease Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Autosomal Dominant Polycystic Kidney Disease Market Drivers and Autosomal Dominant Polycystic Kidney Disease Market Barriers, click here @ Autosomal Dominant Polycystic Kidney Disease Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Autosomal dominant polycystic kidney disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Autosomal dominant polycystic kidney disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bardoxolone methyl: Reata Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GLPG2737: Galapagos NV
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AL 01211: AceLink Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. AT 20494: Anakuria Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Autosomal dominant polycystic kidney disease Key Companies
21. Autosomal dominant polycystic kidney disease Key Products
22. Autosomal dominant polycystic kidney disease- Unmet Needs
23. Autosomal dominant polycystic kidney disease- Market Drivers and Barriers
24. Autosomal dominant polycystic kidney disease- Future Perspectives and Conclusion
25. Autosomal dominant polycystic kidney disease Analyst Views
26. Autosomal dominant polycystic kidney disease Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/